Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

261 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort.
Teira R, Diaz-Cuervo H, Aragão F, Castaño M, Romero A, Roca B, Montero M, Galindo MJ, Muñoz-Sánchez MJ, Espinosa N, Peraire J, Martínez E, de la Fuente B, Domingo P, Deig E, Merino MD, Geijo P, Estrada V, Sepúlveda MA, García J, Berenguer J, Currán A. Teira R, et al. Among authors: castano m. Infect Dis Ther. 2022 Jun;11(3):1177-1192. doi: 10.1007/s40121-022-00630-y. Epub 2022 Apr 11. Infect Dis Ther. 2022. PMID: 35399147 Free PMC article.
Switching to raltegravir in virologically suppressed in HIV-1-infected patients: a retrospective, multicenter, descriptive study.
Podzamczer D, Martínez E, Domingo P, Ferrer E, Viciana P, Curto J, Pérez-Elías MJ, Ocampo A, Santos I, Knobel H, Estrada V, Negredo E, Segura F, Portilla J, Ribera E, Galindo J, Antela A, Carmena J, Castaño M, The Toral Study Group. Podzamczer D, et al. Among authors: castano m. Curr HIV Res. 2012 Dec;10(8):673-8. doi: 10.2174/157016212803901428. Curr HIV Res. 2012. PMID: 23061598
Monotherapy with darunavir/ritonavir is effective and safe in clinical practice.
Pasquau J, López-Cortés L, Mayorga MI, Viciana P, Del Mar Arenas M, Ríos MJ, Hernández-Quero J, Castaño M, Merino MD, Márquez M, Vergara A, Terrón A, Téllez F, Hidalgo-Tenorio C. Pasquau J, et al. Among authors: castano m. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19813. doi: 10.7448/IAS.17.4.19813. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397557 Free PMC article.
Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.
Troya J, Ryan P, Ribera E, Podzamczer D, Hontañón V, Terrón JA, Boix V, Moreno S, Barrufet P, Castaño M, Carrero A, Galindo MJ, Suárez-Lozano I, Knobel H, Raffo M, Solís J, Yllescas M, Esteban H, González-García J, Berenguer J, Imaz A; GESIDA-8314 Study Group. Troya J, et al. Among authors: castano m. PLoS One. 2016 Oct 11;11(10):e0164455. doi: 10.1371/journal.pone.0164455. eCollection 2016. PLoS One. 2016. PMID: 27727331 Free PMC article.
eGFR-EPI changes among HIV patients who switch from F/TDF to F/TAF while maintaining the same third agent in the Spanish VACH cohort.
Teira R, Diaz-Cuervo H, Aragão F, Muñoz J, Galindo P, Merino M, de la Fuente B, Sepúlveda MA, Domingo P, García J, Castaño M, Ribera E, Geijo P, Romero A, Peraire J, Deig E, Roca B, Martínez E, Estrada V, Montero M, Berenguer J, Espinosa N. Teira R, et al. Among authors: castano m. HIV Res Clin Pract. 2021 Jun;22(3):78-85. Epub 2021 Aug 19. HIV Res Clin Pract. 2021. PMID: 34410219
Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study.
Blanco JR, Caro-Murillo AM, Castaño MA, Olalla J, Domingo P, Arazo P, Gómez-Sirvent JL, Riera M, Pulido F, Vera F, Romero-Palacios A, Aguirrebengoa K, Portilla J, Ferrer P, Pedrol E. Blanco JR, et al. Among authors: castano ma. HIV Clin Trials. 2013 Sep-Oct;14(5):204-15. doi: 10.1310/hct1403-204. HIV Clin Trials. 2013. PMID: 24144897
Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.
Troya J, Ryan P, Ribera E, Podzamczer D, Hontañón V, Terrón JA, Boix V, Moreno S, Barrufet P, Castaño M, Carrero A, Galindo MJ, Suárez-Lozano I, Knobel H, Raffo M, Solís J, Yllescas M, Esteban H, González-García J, Berenguer J, Imaz A; GESIDA-8314 Study Group. Troya J, et al. Among authors: castano m. PLoS One. 2017 Feb 9;12(2):e0172184. doi: 10.1371/journal.pone.0172184. eCollection 2017. PLoS One. 2017. PMID: 28182783 Free PMC article.
Safety and Efficacy of Dolutegravir Plus Rilpivirine in Treatment-Experienced HIV-Infected Patients: The DORIVIR Study.
Palacios R, Mayorga M, González-Domenech CM, Hidalgo-Tenorio C, Gálvez C, Muñoz-Medina L, de la Torre J, Lozano A, Castaño M, Omar M, Santos J. Palacios R, et al. Among authors: castano m. J Int Assoc Provid AIDS Care. 2018 Jan-Dec;17:2325958218760847. doi: 10.1177/2325958218760847. J Int Assoc Provid AIDS Care. 2018. PMID: 29529910 Free PMC article.
[HIV in Spain 2017: policies for a new management of chronicity beyond virological control].
Del Amo J, Campbell C, Navarro G, Segura F, Suárez I, Teira R, Brañas F, Serrano-Villar S, Moreno S, Morillo R, Román I, Marrugat J, Fernández E, Marco MP, Blanch J, Castaño M, Pujol F, Fuster MJ, Hernández JS, García-Goñi M, Nuño-Solinís R, Elizondo N, Nuño-Solinís JEDL, Gol-Montserrat J. Del Amo J, et al. Among authors: castano m. Rev Esp Salud Publica. 2018 Sep 6;92:e201809062. Rev Esp Salud Publica. 2018. PMID: 30177678 Spanish.
261 results